Consolidated Adjusted EBITDA. The Consolidated Adjusted EBITDA, as of the last day of each Test Period set forth below, to be less than the amount set forth below opposite such measurement date: Test Period Consolidated Adjusted EBITDA 4 Quarters ending September 30, 2019 $ 2,000,000 4 Quarters ending December 31, 2019 $ 4,000,000 4 Quarters ending March 31, 2020 $ 8,000,000 4 Quarters ending June 30, 2020 $ 14,000,000 4 Quarters ending September 30, 2020 $ 18,000,000
Consolidated Adjusted EBITDA. Holdings shall not permit Consolidated Adjusted EBITDA as at the end of the most-recently-ended Fiscal Month for the trailing twelve-month period then ended (or in the case of any period ended on or prior to May 2, 2009, for the period from May 4, 2008 through the date of determination) to be less than the correlative amount indicated below: Consolidated Adjusted Fiscal Month Ended On or About EBITDA May 31, 2008 ($1,637,000) June 30, 2008 ($1,478,000) July 31, 2008 ($2,445,000) August 30, 2008 ($383,000) September 30, 2008 $1,613,000 October 31, 2008 $8,347,000 November 30, 2008 $23,677,000 December 31, 2008 $28,676,000 January 31, 2009 $20,335,000 February 28, 2009 $21,581,000 March 31, 2009 $22,018,000 April 30, 2009 and each Fiscal Month ended thereafter $23,331,000
Consolidated Adjusted EBITDA. Company shall not permit Consolidated Adjusted EBITDA as at the end of any Fiscal Quarter, beginning with the Fiscal Quarter ending September 30, 2020, for the four Fiscal Quarter period then ended to be less than the correlative amount indicated below (with corresponding calendar quarters also included as reference): Fiscal Quarter Ending Consolidated Adjusted EBITDA (in thousands) September 30, 2020 ($11,179) December 31, 2020 ($10,858) March 31, 2021 ($10,970) 72 Fiscal Quarter Ending Consolidated Adjusted EBITDA (in thousands) June 30, 2021 ($10,888) September 30, 2021 ($11,401) December 31, 2021 ($11,038)
Consolidated Adjusted EBITDA. Company shall not permit Consolidated Adjusted EBITDA as at the end of any Fiscal Quarter, beginning with the Fiscal Quarter ending September 30, 2019, for the four Fiscal Quarter period then ended to be less than the correlative amount indicated below: Fiscal Quarter Consolidated Adjusted EBITDA September 30, 2019 -$17,250,000 December 31, 2019 -$24,000,000 March 31, 2020 -$28,500,000 June 30, 2020 -$23,750,000 September 30, 2020 -$16,500,000 December 31, 2020 -$7,750,000 March 31, 2021 $0 June 30, 2021 $10,000,000 September 30, 2021 $15,000,000 December 31, 2021 until the Maturity Date $20,000,000 For the purposes of determining compliance with the covenant set forth in this Section 6.8(d) following consummation of a Permitted Acquisition each of the minimum Consolidated Adjusted EBITDA amounts set forth in this Section 6.8(d), following the consummation date, shall be increased by 100% of Consolidated Adjusted EBITDA of the entity or assets being acquired for the four Fiscal Quarter period most recently ended prior to the consummation of such Permitted Acquisition.”
Consolidated Adjusted EBITDA. During a Covenant Testing Period, permit the Consolidated Adjusted EBITDA of the Borrower and its consolidated Subsidiaries, as of the last day of any fiscal quarter of the Borrower, on a trailing twelve month basis, to be less than the following: Quarterly Period Ending Adjusted EBITDA (negative Adjusted EBITDA) September 30, 2020 $0.00 December 31, 2020 $0.00 March 31, 2021 ($20,000,000) June 30, 2021 ($20,000,000) September 30, 2021 through and including March 31, 2022 ($25,000,000) June 30, 2022 through and including December 31, 2022 ($15,000,000) March 31, 2023 ($10,000,000) June 30, 2023 and each calendar quarter ending thereafter $0
Consolidated Adjusted EBITDA. Holdings shall not permit Consolidated Adjusted EBITDA as at the end of any Fiscal Quarter, beginning with the Fiscal Quarter ending September 30, 2015, to be less than the correlative number below: Fiscal Quarter Consolidated Adjusted EBITDA For the Fiscal Quarter ending September 30, 2015 $250,000 For the Fiscal Quarter ending December 31, 2015 $1,500,000 For the Fiscal Quarter ending March 31, 2016 $4,250,000 For the Fiscal Quarter ending June 30, 2016 $7,250,000 For the Fiscal Quarter ending September 30, 2016 and each Fiscal Quarter ending thereafter $9,500,000 For the purposes of determining compliance with this Section 6.8(c), Consolidated Adjusted EBITDA as at the end of any Fiscal Quarter shall be equal to (i) with respect to the Fiscal Quarter ending on September 30, 2015, Consolidated Adjusted EBITDA for the Fiscal Quarter ending on such date, (ii) with respect to the Fiscal Quarter ending on December 31, 2015, Consolidated Adjusted EBITDA for the two Fiscal Quarter Period ending on such date, (iii) with respect to the Fiscal Quarter ending on March 31, 2016, Consolidated Adjusted EBITDA for the three Fiscal Quarter period ending on such date, and (iv) with respect to any other Fiscal Quarter, Consolidated Adjusted EBITDA for the period of four consecutive Fiscal Quarters ending on such date. For purposes of clarity, the minimum Consolidated Adjusted EBITDA covenant set forth above is not tested on June 30, 2015.
Consolidated Adjusted EBITDA. Permit Consolidated Adjusted EBITDA for any period of four consecutive fiscal quarters of the Borrower ending with any fiscal quarter set forth below to be less than the amount set forth below opposite such fiscal quarter: Fiscal Quarter Ended Consolidated Adjusted EBITDA March 31, 2004 through September 30, 2004 $ 45,000,000 December 31, 2004 through September 30, 2005 $ 50,000,000 December 31, 2005 through September 30, 2010 $ 55,000,000
Consolidated Adjusted EBITDA. (i) - (ii) = $[ , , ]
Consolidated Adjusted EBITDA. Holdings’ Domestic Subsidiaries and Proliance International de Mexico SA de CV shall not permit Consolidated Adjusted EBITDA as at the end of any testing period, beginning with the month ending July 31, 2007, for the applicable period then ended to be less than the correlative amount indicated: Period Consolidated Adjusted EBITDA 1 month ending July 31, 2007 $1,300,000 2 months ending August 31, 2007 $4,500,000 3 months ending September 30, 2007 $7,600,000 4 months ending October 31, 2007 $9,900,000 5 months November 30, 2007 $12,000,000 Period Consolidated Adjusted EBITDA 12 months ending December 31, 2007 $13,700,000 12 months ending March 31, 2008 $17,800,000 12 months ending June 30, 2008 $24,000,000 12 months ending September 30, 2008 $25,400,000 12 months ending December 31, 2008 $25,400,000 12 months ending March 31, 2009 $26,150,000 12 months ending June 30, 2009 $26,900,000 12 months ending September 30, 2009 $27,650,000 12 months ending December 31, 2009 $28,400,000 12 months ending March 31, 2010 $29,150,000 12 months ending June 30, 2010 $29,900,000 12 months ending September 30, 2010 $30,650,000 December 31, 2010 $31,400,000 March 31, 2011 $32,150,000 June 30, 2011 $32,900,000 September 30, 2011 $33,650,000 December 31, 2011 $34,400,000 March 31, 2012 $35,150,000 June 30, 2012 $35,900,000
Consolidated Adjusted EBITDA. Company shall not permit Consolidated Adjusted EBITDA as at the end of any Fiscal Quarter, beginning with the Fiscal Quarter ending December 31, 2007, for the four Fiscal Quarter period then ended to be less than the correlative amount indicated: Fiscal Quarter Consolidated Adjusted EBITDA December 31, 2007 $ 62,000,000 March 31, 2008 $ 70,000,000 June 30, 2008 $ 80,000,000 September 30, 2008 $ 85,000,000 December 31, 2008 $ 88,000,000 March 31, 2009 $ 91,000,000 June 30, 2009 $ 95,000,000 September 30, 2009 $ 98,000,000 December 31, 2009 and each Fiscal Quarter ending thereafter $ 100,000,000
